Bephacon (1012.362.670): annual accounts, directors and company register

Bephacon

Beveren-Kruibeke-Zwijndrecht ·KBO/BCE: BE 1012.362.670

75-100	Excellent	under 0.55%
60-74	Healthy	0.55% to 1.5%
45-59	Fair	1.5% to 4.2%
25-44	Weak	4.2% to 15.0%
0-24	Critical	over 15.0%

Group	Expected	Actual
1	0.2%	0.2%
2	0.3%	0.5%
3	0.5%	0.6%
4	0.7%	0.8%
5	0.9%	0.9%
6	1.3%	1.5%
7	1.6%	1.8%
8	1.8%	1.8%
9	3.0%	3.1%
10	5.6%	6.2%

Company	Total assets	Gross margin	Solvency	Staff
Bephacon Beveren-Kruibeke-Zwijndrecht	€52,631	€22,905	4.5%	-
PHARMACIE PHARMISTE Brussels	€57,475	€19,564	23.0%	-
9 INTO C Dendermonde	€43,215	€29,890	46.1%	-
HELEPHAR Wingene	€55,332	€29,638	62.2%	-
BUMA PHARMA Antwerp	€57,247	€22,296	67.3%	-
LP SOCIETY Fontaine-l'Evêque	€41,178	€19,602	91.1%	-
Bossiroy Pharma Uccle	€65,695	€27,817	91.4%	-

Line	Trend	2025
Balance sheet: assets
Total assets`20/58`		52,631
Fixed assets`21/28`		2,311
Tangible fixed assets`22/27`		2,311
Plant, machinery and equipment`23`		2,311
Current assets`29/58`		50,320
Amounts receivable within one year`40/41`		13,174
Trade receivables`40`		13,174
Cash at bank and in hand`54/58`		21,431
Deferred charges and accrued income`490/1`		15,715
Balance sheet: equity and liabilities
Total equity and liabilities`10/49`		52,631
Equity`10/15`		2,375
Contributions`10/11`		5,000
Profit (loss) carried forward`14`		-2,625
Amounts payable`17/49`		50,256
Amounts payable within one year`42/48`		46,356
Trade debts`44`		2,205
Suppliers`440/4`		2,205
Taxes, remuneration and social security`45`		9,151
Taxes`450/3`		9,151
Other amounts payable`47/48`		35,000
Accrued charges and deferred income`492/3`		3,900
Income statement
Gross operating margin`9900`		22,905
Depreciation of and write-downs on formation expenses, intangible and tangible fixed assets`630`		19,031
Other operating charges`640/8`		527
Operating profit (loss)`9901`		3,347
Financial income`75/76B`		34
Recurring financial income`75`		34
Financial charges`65/66B`		2,206
Recurring financial charges`65`		2,206
Profit (loss) for the period before taxes`9903`		1,175
Income taxes`67/77`		3,799
Profit (loss) for the period`9904`		-2,625
Profit (loss) for the period to be appropriated`9905`		-2,625
Appropriation of the result
Profit (loss) to be appropriated`9906`		-2,625
Document		PDF

Line	Trend	2025
EBITDA		22,379
Cash flow		16,407
Investment in fixed assets		21,343
Working capital		3,964
Solvency		4.5%
Current ratio		1.09
Debt to equity		21.16
ROE		-110.5%
ROA		-5.0%
Interest coverage		10.14

Item	2025
Tangible fixed assets	€21,343
Depreciation and write-downs of the year	€19,031

BDM² Capital registered office since 31-10-2025	founded in 2025 1033.064.747
Beckers, Bartje (sole trader) establishment since 01-09-2024	founded in 2024 1013.270.116

WIJMENPUT via BECKERS Bartje Marie-Françoise Wilfried, no longer at WIJMENPUT · Director (not named in the articles) · deed of 05-09-2023 founded in 2016	2.3 FTE (2025)
Bepharma via BECKERS Bartje Marie-Françoise Wilfried, no longer at Bepharma · Statutory director · deed of 05-09-2023 No longer active	total assets €1.2m (2025)

Overview

Lifetime

Key points

Turnover

Debts

Starting capital

Checked score

Score breakdown

Comparable companies, two years later

Signals

Board and ownership

Recent changes

Comparable companies

Official details

Annual accounts 2025

Insights on Bephacon

Financials

Annual accounts 2025

Balance sheet

Position in the sector

Solvency4.5%

Current ratio1.09

Return on assets-5.0%

Filed annual accounts

Filings

Key figures and ratios

Investments

Insights on Bephacon

Board & ownership

Board

Mandates through the years

Control

Capital

Articles of association

Shareholders

Network & group

No group

At the same address

Earlier ties

Connections & network

Timeline

Timeline

Company details

Identity

Activities

Registered office and establishments

Buildings and parcels at the address

Location

Parcels